Novartis invests $55m in US gene therapy site, prepares BLA

By Flora Southey contact

- Last updated on GMT

Getty/AndreyKrav
Getty/AndreyKrav
AveXis – a Novartis company – has added a manufacturing facility in North Carolina to its site network, where it will make investigational therapies for neurological genetic diseases.

The clinical-stage gene therapy firm will invest $55m into the site – located in Research Triangle Park, North Carolina, US – and add 200 jobs in engineering, manufacturing and quality control, and supply chain roles.

“As a long-established biotechnology hub that attracts the nation’s top talent, Research Triangle Park was an optimal location to expand our footprint and complement our existing state-of-the-art manufacturing site in the Chicagoland area,” ​said chief technical officer Andrew Knudten said in a statement​.

Other pharmaceutical firms to occupy sites in Research Triangle Park include GlaxoSmithKline​ and Biogen​.

BLA preparations

When Novartis acquired AveXis for $8.7bn in May this year​, it picked up the biotech’s investigational gene therapy AVXS-101, designed to treat spinal muscular atrophy (SMA).

An AveXis spokesperson told us the firm is preparing to submit the candidate to the US Food and Drug Administration (FDA) for review: “A pre-BLA [biologics license application] is scheduled with the US FDA in June surrounding the regulatory pathway for AVXS-101 for the treatment of SMA.”

“There are preclinical assets in development for the treatment of genetic ALS [amyotrophic lateral sclerosis] and Rett syndrome, for which AveXis anticipates a submission of INDs [investigational new drug] late 2018 or Q1 2019,” ​she added.

Novartis is not new to the gene therapy space. The Big Pharma company received FDA approval for chimeric antigen receptor (CAR) T-cell therapy Kymriah (tisagenlecleucel) in August last year​.

And last month​, the FDA approved Kymriah for a second indication – to treat adult patients with relapsed or refractory (r/r) large B-cell lymphoma – making it the only CAR T-cell therapy to receive US regulatory approval for two distinct indications

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars